U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07467447) titled 'Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight' on March 08.
Brief Summary: Phase 2, multicenter, randomized, double-blind, placebo-controlled study evaluating once-weekly subcutaneous retatrutide (LY3437943) at multiple maintenance dose levels versus placebo in adults with obesity or overweight with weight-related comorbidities (without type 2 diabetes), alongside standardized diet and physical activity counseling.
Study Start Date: Feb. 15
Study Type: INTERVENTIONAL
Condition:
Obesity
Intervention:
DRUG: Retatrutide (LY3437943)
subcutaneous injection, once weekly (dose per assigned ar...